Metastatic Breast Cancer HR+ research hub

SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.

This study looks at new ways to treat advanced breast cancer that has spread. It's for women with a specific type of hormone-positive breast cancer. Researchers are comparing two different drug combinations to see which works best at stopping the cancer from growing.